Antidepressants in panic disorder

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 2, 1997, Pages 20-24

  Jefferson, James W ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Dean Foundation for Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; BROFAROMINE; CHLORDIAZEPOXIDE; CLOMIPRAMINE; FLUVOXAMINE; IMIPRAMINE; INOSITOL; LOFEPRAMINE; MAPROTILINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZIMELDINE;

CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FOOD DRUG INTERACTION; HUMAN; HUMAN TISSUE; META ANALYSIS; PANIC; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IMIPRAMINE; MONOAMINE OXIDASE INHIBITORS; PANIC DISORDER; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0030988949     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Clevenger SV. Heart disease in insanity and a case of panphobia. Alienist and Neurologist 1890;7:435-543
2. Wilkinson G, Balestrieri M, Ruggeri M, et al. Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders. Psychol Med 1991;21:991-998
3. Judd FK, Norman TR, Burrows GD. Pharmacological treatment of panic disorder. Int Clin Psychopharmacol 1986;1:3-16
4. Matuzas W, Jack E. The drug treatment of panic disorder. Psychiatr Med 1991;9:215-243
5. Lydiard RB, Ballenger JC. Antidepressants in panic disorder and agoraphobia. J Affect Disord 1987;13:153-168
6. Bowden CL. Psychopharmacological treatment of panic disorder. Bull Menninger Clin 1992;56(2, suppl):A29-A41
7. Johnson MR, Lydiard RB, Ballenger JC. Panic disorder: pathophysiology and drug treatment. Drugs 1995;49:328-344
8. Layton ME, Dager SR. Optimum treatment of panic disorder. CNS Drugs 1994;2:208-215
9. Agras WS. The diagnosis and treatment of panic disorder. Annu Rev Med 1993;44:39-51
10. Rosenberg R. Drug treatment of panic disorder. Pharmacol Toxicol 1993;72:344-353
11. Pollack MH, Otto MW. Long-term pharmacologic treatment of panic disorder. Psychiatr Ann 1994;24:291-298
12. Ballenger JC. Panic disorder: efficacy of current treatments. Psychopharmacol Bull 1993;29:477-486
13. Rosenbaum JF, Pollock RA, Otto MW, et al. Integrated treatment of panic disorder. Bull Menninger Clin 1995;59(2, suppl):A4-A26
14. Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry 1962;119:432-438
15. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964;5:397-408
16. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995;10:45-49
17. Cassano GB, Petracca A, Perugi G, et al. Clomipramine for panic disorder, I: the first 10 weeks of a long-term comparison with imipramine. J Affect Disord 1988;14:123-127
18. Judd FK, Burrows GD, Marriott PF, et al. A short-term open trial of clomipramine in the treatment of patients with panic attacks. Hum Psychopharmacol 1991;6:53-60
19. Kahn RS, Westenberg HGM, Verhoeven WMA, et al. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders: a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 1987;2:33-45
20. Gloger S, O'Ryan F, Gladic D, et al. Panic anxiety: diazepam/clomipramine comparison. In: New Research Programs and Abstracts of the 143rd Annual Meeting of the American Psychiatric Association; May 12-17, 1990; New York, NY Abstract NR314
21. Fahy TJ, O'Rourke D, Brophy J, et al. The Galway study of panic disorder, I: clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. J Affect Disord 1992;25:63-76
22. Den Boer JA, Westenberg HGM, Kamerbeek WDJ, et al. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21-32
23. Gentil V, Lotufo-Neto F, Andrade L, et al. Clomipramine, a better reference drug for panic/agoraphobia, I: effectiveness comparison with imipramine. J Psychopharmacol 1993;7:316-324
24. Johnston DG, Troyer IE, Whitsett SF. Clomipramine treatment of agoraphobic women. Arch Gen Psychiatry 1988;45:453-459
25. Johnston DG, Troyer IE, Whitsett SF, et al. Clomipramine treatment and behaviour therapy with agoraphobic women. Can J Psychiatry 1995;40: 192-199
26. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992;12:251-261
27. Kalus O, Asnis GM, Rubinson E, et al. Desipramine treatment in panic disorder. J Affect Disord 1991;21:239-244
28. Lydiard RB. Desipramine in agoraphobia with panic attacks: an open, fixed-dose study. J Clin Psychopharmacol 1987;7:258-260
29. Lydiard RB, Morton A, Emmanuel NP, et al. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 1993;29:183-188
30. Munjack DJ, Usigli R, Zulueta A, et al. Nortriptyline in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1988;8:204-207
31. West ED, Dally PJ. Effects of iproniazid in depressive syndromes. BMJ 1959;1:1491-1494
32. Sargant W, Dally P. Treatment of anxiety states by antidepressant drugs. BMJ 1962;1:6-9
33. Lipsedge MS, Hajioff J, Huggins P, et al. The management of severe agoraphobia: a comparison of iproniazid and systematic desensitization. Psychopharmacologia 1973;32:67-80
34. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37:51-59
35. Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987; 48:55-59
36. Garcia-Borreguero D, Lauer CJ, Özdaglar A, et al. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A. Pharmacopsychiatry 1992;5:261-264
37. van Vliet IM, Westenberg HGM, den Boer JA. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. Psychopharmacology 1993;112:483-489
38. Bakish D, Saxena BM, Bowen R, et al. Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacol 1993;16(2, suppl): S77-S82
39. den Boer JA, van Vliet IM, Westenberg HGM. A double blind comparative study of fluvoxamine and brofaromine in panic disorder [abstract]. Clin Neuropharmacol 1992;15(1, suppl: part B):91B
40. Volz HP, Gleiter CH, Struck M, et al. Brofaromine: insight into the nature of drug development. CNS Drugs 1995;3:1-8
41. Bakish D, Filteau MJ, Charbonneau Y, et al. A double-blind, placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. In: Neuropsychopharmacology, pt 2, Oral Communications and Poster Abstracts of the XIXth Collegium International Neuropsychopharmacologicum Congress; June 27-July 1, 1994; Washington, DC. Abstract 0-27-38
42. Hoehn-Saric R, Fawcett J, Munjack DJ, et al. A multicentre, double-blind, placebo-controlled study of fluvoxamine in the treatment of panic disorder. In: Neuropsychopharmacology, pt 2, Oral Communications and Poster Abstracts of the XIXth Collegium International Neuropsychopharmacologicum Congress; June 27-July 1, 1994; Washington, DC. Abstract P-58-33
43. Woods S, Black D, Brown S, et al. Fluvoxamine in the treatment of panic disorder in outpatients: a double-blind, placebo-controlled study. In: Neuropsychopharmacology, pt 2, Oral Communications and Poster Abstracts of the XIXth Collegium International Neuropsychopharmacologicum Congress; June 27-July 1, 1994; Washington, DC. Abstract P-58-37
44. Black DW, Wesner R, Bowers W, et al. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;52:44-50
45. Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13:321-326
46. de Beurs E, van Balkom AJLM, Lange A, et al. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995;152:683-691
47. den Boer JA, Westenberg HGM, Kamerbeek WD, et al. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21-32
48. den Boer JA, Westenberg HGM. Effect of serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3: 59-74
49. den Boer JA, Westenberg HGM. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 1990;102:85-94
50. Schneier FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990;10:119-121
51. Bystritsky A, Rosen RM, Murphy KJ, et al. Double-blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety 1994/1995;1:287-290
52. Altshuler LL. Fluoxetine-associated panic attacks. J Clin Psychopharmacol 1994;14:433-434
53. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993;54:435-438
54. Dunbar GC. A double-blind placebo controlled study of paroxetine and clomipramine in the treatment of panic disorder. In: Program and Abstracts on New Research of the 148th Annual Meeting of the American Psychiatric Association; May 20-25, 1995; Miami, Fla. Abstract NR376
55. Steiner M, Oakes R, Gergel IP, et al. A fixed dose study of paroxetine and placebo in the treatment of panic disorder. In: Program and Abstracts on New Research of the 148th Annual Meeting of the American Psychiatric Association; May 20-25, 1995; Miami, Fla. Abstract NR355
56. Oehrberg PE, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-379
57. Gorman J, Wolkow R. Sertraline as a treatment for panic disorder. In: Neuropsychopharmacology, pt 2, Oral Communications and Poster Abstracts of the XIXth Collegium International Neuropsychopharmacologicum Congress; June 27-July 1, 1994; Washington, DC. Abstract P-117-175
58. Zinner SH. Panic attacks precipitated by sertraline [letter]. Am J Psychiatry 1994;151:147-148
59. Geracioti TD Jr. Venlafaxme treatment of panic disorder: a case series. J Clin Psychiatry 1995;56:408-410
60. Sheehan DV, Davidson J, Manschreck T, et al. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 1983;3:28-31
61. Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986;47:580-586
62. Mavissakalian M, Perel J, Bowler K, et al. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry 1987; 144:785-787
63. Benjamin J, Levine J, Fux M, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995;152:1084-1086
64. Mavissakalian M, Perel JM. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry 1992;149: 1053-1057